There was more bad news for Eli Lilly following the spectacular failure of its late-stage Alzheimer’s disease candidate, and a new question mark over the future of Cymbalta in chronic pain.
|
BioMarin’s stock inched up yesterday on news that it has hit the acquisition trail again gaining access to a potential new Pompe disease drug by snapping up private biotech ZyStor Therapeutics in a deal worth up to $115 million.
|
Shire Pharmaceuticals has announced plans to pull its hypotension drug ProAmatime from the market, following reports yesterday that US regulators are preparing to withdraw its approval
|
German drugmaker Bayer AG has reportedly pulled $60 million out of its wallet to settle around 150 lawsuits relating to its blood loss agent Trasylol, which was yanked from the market in 2007 on safety concerns.
|